Next to surgery, radiation is the most effective treatment for malignant brain tumors. Nonetheless, -20% of glioblastoma multiforme (GBM) progress during the course of radiation therapy, suggesting that these lesions are resistant to radiation. Using tissues obtained during surgery, we will develop laboratory methodologies for identifying these tumors, and will quantify their response to radiation. Radiation sensitivity of mammalian cells is determined in the laboratory by measuring cell killing. However, for primary tumor tissue this approach is problematic because of low plating efficiencies and the resultant selection for study of a very small fraction of the original tumor cell population. Attempts to develop predictive assays based on brain tumor cell survival as the end-point have failed. We believe that it is crucial to determine whether other quantitative measures can be used to predict tumor response to radiation therapy. We propose to assess intrinsic radiation response with methods more suitable for use in primary tumor samples: measurement of DNA double strand breaks by pulsed field gel electrophoresis; NA supercoiling changes by the nucleoid halo assay; and measurement of chromosomal breaks and exchanges using fluorescence in situ hybridization techniques. We will determine hypoxic fraction in selected tumors using the comet assay. We will determine which of these assays provides relevant information regarding the radiation response of human brain tumor cells and establish predictive assays. Because of the problems inherent in studying radiation sensitivity of explanted tumors outside of their natural milieu, we will study the feasibility of irradiating malignant brain tumors in situ with a low energy X-ray source intraoperatively and harvesting tissue at intervals to measure DNA damage and repair and tumor hypoxia. This may be the ideal way to study the individual tumor's sensitivity to radiation.
Our specific aims are: 1) to define the optimal experimental conditions to quantify DNA damage and repair and hypoxic fraction in human brain tumor tissue grown as a xenograft model; 2) to determine which of the assays studied in Aim 1 show(s) the most promise as a predictive assay for in vivo radiation responsiveness in xenograft models; 3) to measure DNA damage and repair and chromosome breaks and exchanges in fresh GBM specimens using optimal conditions for the chosen assay(s); 4) to investigate the feasibility of irradiating human brain tumors at surgery with allow energy X-ray source and harvesting tumor tissue for assays of hypoxic fraction and DNA damage and repair; and, 5) to correlate the results obtained in Aim 3 with the tumor's BUdR labeling index and potential doubling time, genetic aberrations, activity of the DNA repair enzyme O/6-AT, and with established clinical indicators of prognosis, and clinical measures of radiation therapy outcome.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA013525-23
Application #
3728728
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
23
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Rodriguez, Fausto J; Tihan, Tarik; Lin, Doris et al. (2014) Clinicopathologic features of pediatric oligodendrogliomas: a series of 50 patients. Am J Surg Pathol 38:1058-70
Chang, Susan M; Parney, Ian F; Huang, Wei et al. (2005) Patterns of care for adults with newly diagnosed malignant glioma. JAMA 293:557-64
Parney, Ian F; Kunwar, Sandeep; McDermott, Michael et al. (2005) Neuroradiographic changes following convection-enhanced delivery of the recombinant cytotoxin interleukin 13-PE38QQR for recurrent malignant glioma. J Neurosurg 102:267-75
Prados, Michael D; Seiferheld, Wendy; Sandler, Howard M et al. (2004) Phase III randomized study of radiotherapy plus procarbazine, lomustine, and vincristine with or without BUdR for treatment of anaplastic astrocytoma: final report of RTOG 9404. Int J Radiat Oncol Biol Phys 58:1147-52
Levin, Victor A; Hess, Kenneth R; Choucair, Ali et al. (2003) Phase III randomized study of postradiotherapy chemotherapy with combination alpha-difluoromethylornithine-PCV versus PCV for anaplastic gliomas. Clin Cancer Res 9:981-90
McKnight, Tracy R; von dem Bussche, Mary H; Vigneron, Daniel B et al. (2002) Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. J Neurosurg 97:794-802
Hamel, W; Zirkel, D; Mehdorn, H M et al. (2001) (E)-5-(2-bromovinyl)-2'-deoxyuridine potentiates ganciclovir-mediated cytotoxicity on herpes simplex virus-thymidine kinase--expressing cells. Cancer Gene Ther 8:388-96
Simmons, M L; Lamborn, K R; Takahashi, M et al. (2001) Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. Cancer Res 61:1122-8
Hamel, W; Dazin, P; Israel, M A (1996) Adaptation of a simple flow cytometric assay to identify different stages during apoptosis. Cytometry 25:173-81
Hamel, W; Magnelli, L; Chiarugi, V P et al. (1996) Herpes simplex virus thymidine kinase/ganciclovir-mediated apoptotic death of bystander cells. Cancer Res 56:2697-702

Showing the most recent 10 out of 14 publications